NKTR Nektar Therapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: NKTR

Price (delayed)

$1.38

Market cap

$253.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.92

Enterprise value

$318.84M

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. ...

Highlights
Nektar Therapeutics's EPS has surged by 58% YoY and by 37% QoQ
The net income has surged by 58% year-on-year and by 36% since the previous quarter
Nektar Therapeutics's equity has decreased by 47% YoY and by 3.3% QoQ
Nektar Therapeutics's quick ratio has decreased by 27% YoY and by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nektar.com
Peers: PFE MRK AMGN ENZN

Key stats

What are the main financial stats of NKTR
Market
Shares outstanding
183.62M
Market cap
$253.4M
Enterprise value
$318.84M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2
Price to sales (P/S)
2.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.54
Earnings
Revenue
$90.17M
EBIT
-$151.55M
EBITDA
-$144.43M
Free cash flow
-$187.92M
Per share
EPS
-$0.92
Free cash flow per share
-$0.96
Book value per share
$0.69
Revenue per share
$0.46
TBVPS
$2.03
Balance sheet
Total assets
$396.01M
Total liabilities
$269.31M
Debt
$114.08M
Equity
$126.71M
Working capital
$267.43M
Liquidity
Debt to equity
0.9
Current ratio
6.1
Quick ratio
5.59
Net debt/EBITDA
-0.45
Margins
EBITDA margin
-160.2%
Gross margin
60.9%
Net margin
-195%
Operating margin
-182.3%
Efficiency
Return on assets
-40.6%
Return on equity
-114.6%
Return on invested capital
-33.6%
Return on capital employed
-44.1%
Return on sales
-168.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
0.73%
1 week
-0.72%
1 month
27.78%
1 year
157.46%
YTD
144.25%
QTD
11.29%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$90.17M
Gross profit
$54.93M
Operating income
-$164.4M
Net income
-$175.84M
Gross margin
60.9%
Net margin
-195%
The operating margin has soared by 59% YoY and by 38% from the previous quarter
The net margin has soared by 58% YoY and by 36% QoQ
The operating income has soared by 58% year-on-year and by 38% since the previous quarter
The net income has surged by 58% year-on-year and by 36% since the previous quarter

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
2
P/S
2.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.54
Nektar Therapeutics's EPS has surged by 58% YoY and by 37% QoQ
The P/B is 121% above the last 4 quarters average of 0.9 but 5% below the 5-year quarterly average of 2.1
Nektar Therapeutics's equity has decreased by 47% YoY and by 3.3% QoQ
The stock's P/S is 111% more than its last 4 quarters average of 1.4 but 81% less than its 5-year quarterly average of 15.6

Efficiency

How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's return on sales has surged by 61% YoY and by 40% QoQ
The return on invested capital has grown by 44% year-on-year and by 35% since the previous quarter
NKTR's ROA is up by 30% from the previous quarter and by 29% YoY
Nektar Therapeutics's ROE has increased by 24% from the previous quarter but it has decreased by 2.1% YoY

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 47% more than its total liabilities
Nektar Therapeutics's total assets has decreased by 30% YoY
Nektar Therapeutics's quick ratio has decreased by 27% YoY and by 6% from the previous quarter
The debt is 10% lower than the equity
The debt to equity has soared by 70% YoY
Nektar Therapeutics's equity has decreased by 47% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.